When Sarah Mitchell (a pseudonym) opened the letter from her insurance company last November, she expected a routine update. Instead, she found a denial notice for her antidepressant, a medication she had taken for three years. Within hours, she was in an emergency room in Phoenix, Arizona, clutching her chest and struggling to breathe. “I felt like I was dying,” she recalls. “The panic came out of nowhere.”

Mitchell’s story is not unusual. Across the United States, emergency department visits for panic attacks have risen roughly 40% from 2019 to 2024, according to data from the Agency for Healthcare Research and Quality (AHRQ). A growing body of evidence ties this surge to a specific trigger: prior authorization denials for mental health medications. A 2025 survey by the American Psychiatric Association (APA) found that one in three patients whose insurance denied coverage for a psychiatric drug reported symptoms consistent with a panic attack within days of receiving the denial. The denial letter, once a bureaucratic annoyance, is increasingly a medical event.

When a Paper Denial Becomes a Panic Attack

The link between a denial letter and a panic attack is not metaphorical. For patients stabilized on a specific medication, an abrupt interruption can trigger withdrawal symptoms, rebound anxiety, and a sense of hopelessness. “The prior authorization process is designed to contain costs, but it doesn’t account for the physiological and psychological dependence a patient may have on a drug,” says Dr. Lisa Chang, a psychiatrist at the University of Michigan. “When you tell someone they can’t have their medication, you’re effectively prescribing a crisis.”

James Thompson (a pseudonym), a 34-year-old teacher in Columbus, Ohio, experienced this firsthand. His insurer denied coverage for his anxiety medication, citing a requirement to first try a cheaper generic. “I knew the generic didn’t work for me—I’d tried it before,” he says. “But the insurance said I had to fail it again.” Two days after stopping his medication, Thompson had a panic attack at his desk. “My heart was pounding, I was sweating, and I couldn’t think straight. My colleague drove me to the ER.”

Survey data from the National Alliance on Mental Illness (NAMI) corroborates these anecdotes. Among patients who experienced a prior authorization denial for a psychiatric medication, 34% reported visiting an emergency room for mental health reasons within 30 days. Another 22% said they had suicidal thoughts. “The denial doesn’t just delay care,” says NAMI policy director Rachel Morrison. “It actively worsens the underlying condition and pushes people into crisis.”

Clinicians describe a pattern: patients receive a denial letter, often without a clear clinical rationale. They panic. They call their doctor, who may be unavailable. They run out of medication. Symptoms escalate. The emergency room becomes the only option. “We see it all the time,” says Dr. Mark Rivera, an emergency physician in Denver. “Someone comes in with a panic attack, and the root cause is almost always an insurance issue.”

The Prior Authorization Pipeline: How a Gatekeeping Tool Drives Crisis

Prior authorization is a process insurers use to require pre-approval before covering certain drugs or procedures. It is intended to control costs and ensure appropriate use. But for mental health medications, the process has become a bottleneck. A 2024 survey by the American Medical Association (AMA) found that 94% of physicians report care delays attributable to prior authorization. For psychiatric drugs, the denial rate is particularly high: some estimates suggest that roughly 15–20% of antidepressant prescriptions are initially denied, compared to about 8% for non-psychiatric drugs.

Commonly denied medications include selective serotonin reuptake inhibitors (SSRIs) like sertraline and escitalopram, as well as benzodiazepines and antipsychotics. Many plans require step therapy—patients must try and fail one or more cheaper alternatives before the insurer will cover the doctor’s preferred drug. “Step therapy makes sense for some conditions, but for mental health, it can be dangerous,” says Dr. Chang. “You’re asking a depressed patient to spend weeks on a drug that might not work, or could cause side effects, while their condition deteriorates.”

The denial letter itself often lacks clinical detail. “It will say ‘not medically necessary’ without explaining why,” says Morrison. “Patients are left to navigate an appeals process that is confusing and time-sensitive.” Appeals must typically be filed within 60 days, but many patients lack the energy or knowledge to do so. A 2023 study in Health Affairs found that fewer than 10% of denied patients appeal the decision. Those who do appeal succeed about half the time, but the process can take weeks—time during which symptoms worsen.

For some patients, the denial is compounded by formulary changes. Insurers periodically update their lists of covered drugs, moving a patient’s medication to a non-preferred tier or dropping it entirely. “I’d been on the same drug for five years,” says Thompson. “Then one day, my pharmacy said my insurance wouldn’t cover it anymore. No warning, no explanation.” He was given a 30-day supply to transition, but the new drug caused severe side effects, and he stopped taking it. Within a week, he was in the ER.

Emergency Room as Default Mental Health Safety Net

The emergency department has become the default safety net for mental health crises, but it is ill-equipped to handle them. Psychiatric boarding times—the hours patients wait in the ER for a psychiatric bed or evaluation—average 12 to 24 hours nationally, and can exceed 48 hours in some regions. During that time, patients are often held in a hallway or a curtained bay, with minimal mental health support. “We can treat the acute panic symptoms—give a benzodiazepine, monitor vitals—but we’re not set up to provide ongoing psychiatric care,” says Dr. Rivera.

The surge in panic attack visits has strained ER resources. Data from the Centers for Disease Control and Prevention (CDC) show that mental health-related ER visits increased by roughly 40% between 2019 and 2024, with panic attacks accounting for a growing share. Many hospitals lack on-call psychiatrists; a 2022 survey by the American College of Emergency Physicians found that only about 40% of ERs have access to a psychiatrist within 30 minutes. “We’re seeing patients who need medication management, not emergency care,” says Dr. Rivera. “But they have nowhere else to go.”

The cost of an ER visit for a panic attack is steep. A single visit can cost between US$1,200 and US$2,400, depending on the hospital and region, according to data from the Health Care Cost Institute. That is roughly 3 to 5 times the cost of a month’s supply of an antidepressant. For uninsured or underinsured patients, the bill can be devastating. “I got a US$1,800 bill for a four-hour ER visit,” says Mitchell. “I’d rather have just bought the medication out of pocket, but I couldn’t afford it either.”

Patients often leave the ER with a prescription for a short-term medication, such as a benzodiazepine, but no follow-up plan. “We give them a few pills and tell them to see a psychiatrist,” says Dr. Rivera. “But getting an appointment can take weeks. And if their insurance won’t cover the follow-up, they’re back in the ER.”

Worse Outcomes, Higher Costs: The System’s Self-Defeating Logic

The irony of prior authorization is that it often ends up costing the system more, not less. Delayed or interrupted treatment for depression and anxiety leads to worsening symptoms, higher hospitalization rates, and greater use of emergency services. A 2024 study in JAMA Psychiatry found that patients with depression whose antidepressants were denied through prior authorization had a 15% higher rate of psychiatric hospitalization within six months, compared to those whose prescriptions were approved. The cost of that hospitalization—often US$5,000 to US$10,000—far exceeds the cost of the medication.

Emergency room visits are similarly expensive. The average cost of a mental health-related ER visit is about US$1,500, according to a 2023 analysis by the Kaiser Family Foundation. By contrast, a month’s supply of a generic antidepressant costs roughly US$20 to US$60. “From a pure cost perspective, it makes no sense to deny these drugs,” says Dr. Chang. “The savings are pennies, and the downstream costs are enormous.”

Insurers argue that prior authorization is necessary to prevent overprescribing and to steer patients toward evidence-based treatments. “Step therapy can ensure that patients try first-line therapies before moving to more expensive options,” says a spokesperson for America’s Health Insurance Plans (AHIP). “The goal is to maximize value, not to deny care.” But critics counter that the process is applied too rigidly, without accounting for individual patient history. “One size does not fit all in mental health,” says Morrison. “These are complex conditions that require individualized treatment.”

The financial burden also falls on patients. Many skip doses or stop taking medication after a denial, which can precipitate a crisis. A 2025 survey by the Commonwealth Fund found that 18% of adults with private insurance reported not filling a prescription in the past year due to cost or insurance problems. Among those with mental health conditions, the rate was 29%. “It’s a false economy,” says Dr. Rivera. “You save US$50 on a prescription, but you spend US$2,000 on an ER visit. The patient suffers, and the system pays more.”

Who Bears the Brunt: Disparities in Denial and ER Use

The burden of prior authorization denials is not evenly distributed. Medicaid patients face denial rates nearly double those of patients with private insurance, according to a 2024 report from the Office of the Inspector General. In some states, denial rates for psychiatric drugs under Medicaid exceed 30%. “Medicaid patients are already vulnerable,” says Dr. Chang. “They have fewer resources to navigate the appeals process, and they often have fewer alternative providers.”

Rural residents also suffer disproportionately. With fewer outpatient mental health providers, they are more likely to rely on emergency rooms for routine care. A 2023 study in Health Services Research found that rural residents were 25% more likely to visit an ER for a mental health condition than urban residents, even after controlling for income and insurance status. “If your only option is the ER, you’re going to end up there,” says Dr. Rivera.

Racial and ethnic disparities compound the problem. Non-white patients are less likely to appeal a denial successfully, often due to language barriers or lack of familiarity with the insurance system. A 2022 study in Psychiatric Services found that Black and Hispanic patients were 40% less likely to have a prior authorization appeal granted than white patients. “The system is designed for people who know how to work it,” says Morrison. “If you don’t speak English fluently or you don’t have a computer, you’re at a huge disadvantage.”

Low-income patients often face the cruelest calculus: after a denial, they may choose to skip the medication entirely rather than pay full price. “I couldn’t afford US$300 for the brand-name drug, so I just went without,” says Mitchell. “I figured I’d be fine. But I wasn’t.” The result is a cycle of crisis, ER use, and debt that is hard to break.

Policy Fixes That Could Break the Cycle

Several policy changes could reduce the number of patients who spiral from denial to ER. A handful of states—including California, New York, and Texas—have passed laws requiring insurers to make prior authorization decisions for mental health drugs within 24 hours for urgent requests. “Real-time decisions can prevent a patient from running out of medication,” says Morrison. “It’s a simple fix that could save lives.”

Another approach is “gold card” programs, which exempt high-performing providers from prior authorization requirements. Under these programs, physicians who have a high rate of approved prescriptions are automatically exempted from future prior authorization for those drugs. “It reduces the burden on both doctors and patients,” says Dr. Chang. “And it incentivizes insurers to focus on the outliers.”

At the federal level, the Centers for Medicare & Medicaid Services (CMS) has proposed a rule that would require all insurers to use electronic prior authorization systems by 2027, streamlining the process and reducing delays. The rule would also require insurers to provide a specific clinical reason for denials. “Transparency is key,” says Morrison. “If a patient knows why a drug was denied, they can work with their doctor to address it.”

Integrated care models that embed mental health services in primary care settings have also shown promise. A 2023 study in Health Affairs found that patients in integrated care programs were 30% less likely to visit an ER for mental health reasons. “When you have a primary care doctor who can manage your depression, you don’t need to go to the ER,” says Dr. Rivera. “But that requires insurers to pay for those services.”

Despite these promising reforms, progress is slow. Insurers have pushed back against gold card programs, arguing that they could increase costs. And many states have yet to pass any prior authorization reform. “The system is resistant to change,” says Morrison. “But the data are clear: the current approach is hurting patients and costing everyone more.”

What Patients Can Do While Waiting for Reform

For patients currently navigating a denial, there are steps that may help avoid a crisis. First, ask your clinician to document medical necessity in the appeal letter. “A detailed letter from a doctor explaining why a specific drug is needed can make a big difference,” says Dr. Chang. “Include information about past treatment failures, side effects, and why the alternative is not appropriate.”

Second, request a formulary exception if your drug is non-preferred. Insurers often have a process for covering drugs not on their preferred list, but patients must ask for it. “It’s not well-publicized, but it exists,” says Morrison. “Your doctor may need to submit a request, but it can be worth it.”

Third, contact your state insurance commissioner if you believe the denial was made in bad faith. Every state has an insurance regulatory agency that handles complaints. “If you’ve been denied without a clear reason, or if the insurer is not following its own rules, file a complaint,” says Morrison. “It can trigger an investigation.”

Finally, patient assistance programs offered by pharmaceutical companies can provide free or reduced-cost medications to those who qualify. “It’s not a long-term solution, but it can bridge the gap,” says Dr. Rivera. “And have a crisis plan with your provider—know what to do if symptoms escalate, so you don’t have to default to the ER.”

These steps are not guarantees, but they can buy time—time that might prevent a panic attack, an ER visit, and a bill that could take years to pay off. As the debate over prior authorization continues, patients like Mitchell and Thompson remain caught in the middle. “I just want to get my medication without having to fight for it,” says Mitchell. “Is that too much to ask?”

Disclaimer: This article is for informational purposes only and does not constitute personalized medical or insurance advice. Patients should consult their healthcare provider for guidance specific to their situation.